HUP0300867A2 - Aril-szubsztituált pirazolok, triazolok és tetrazolok és alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények - Google Patents
Aril-szubsztituált pirazolok, triazolok és tetrazolok és alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0300867A2 HUP0300867A2 HU0300867A HUP0300867A HUP0300867A2 HU P0300867 A2 HUP0300867 A2 HU P0300867A2 HU 0300867 A HU0300867 A HU 0300867A HU P0300867 A HUP0300867 A HU P0300867A HU P0300867 A2 HUP0300867 A2 HU P0300867A2
- Authority
- HU
- Hungary
- Prior art keywords
- compounds
- formula
- alkyl
- subject
- hydrogen atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical class C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003217 pyrazoles Chemical class 0.000 title 1
- 150000003536 tetrazoles Chemical class 0.000 title 1
- 150000003852 triazoles Chemical class 0.000 title 1
- -1 nitro- Chemical class 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000028389 Nerve injury Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 208000009205 Tinnitus Diseases 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 1
- 230000003288 anthiarrhythmic effect Effects 0.000 abstract 1
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 208000028683 bipolar I disease Diseases 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 238000002690 local anesthesia Methods 0.000 abstract 1
- 230000008764 nerve damage Effects 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 1
- 231100000886 tinnitus Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A találmány tárgyát az (I) általános képletű vegyületek azokgyógyászatilag elfogadható sói, elővegyületei vagy szolvátjai képezik,ahol a képletben X jelentése O, S, NR9, CH2, NR9C(O) vagy C(O)NR9,ahol R9 jelentése hidrogénatom vagy C1-10 alkilcsoport; Het jelentéseaz (i), (ii), (iii) vagy (iv) általános képletű csoportok közülválasztott, ahol R5, R6, R7 és R8 jelentése egymástól függetlenül akövetkező csoportból választott: hidrogénatom, halogénatom,haloalkil-, alkil-, alkenil-, alkinil-, hidroxialkil-, aminoalkil-,karboxilalkil-, alkoxialkil-, nitro-, amino-, ureido-, ciano-,acilamino-, amid-, hidroxil-, tiol-, aciloxi-, azido-, alkoxi-,karboxil-, karbonilamido és alkiltiocsoport; ahol egyesszubsztituenskombinációk kizártak. A találmány tárgyát képezi továbbáa fenti vegyületek gyógyszerkészítmény előálítására való alkalmazásais. A vegyületek nátriumcsatorna-gátló hatásúak, így elsősorban akövetkező betegségek esetében hasznosíthatóak: globális és fokálisisémia okozta idegkárosodás, neurodegeneratív állapotok, tinnitusz,fájdalom, mániákus depresszió, helyi érzéstelenítésre, antiaritmia ésgörcs. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19175700P | 2000-03-24 | 2000-03-24 | |
PCT/US2001/008972 WO2001072714A2 (en) | 2000-03-24 | 2001-03-22 | Aryl substituted pyrazoles, triazoles and tetrazoles as sodium channel blocker |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0300867A2 true HUP0300867A2 (hu) | 2003-07-28 |
HUP0300867A3 HUP0300867A3 (en) | 2004-11-29 |
HU229371B1 HU229371B1 (en) | 2013-11-28 |
Family
ID=22706817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0300867A HU229371B1 (en) | 2000-03-24 | 2001-03-22 | Aryl substituted pyrazoles, triazoles and tetrazoles, and the use thereof |
Country Status (21)
Country | Link |
---|---|
US (2) | US7078426B2 (hu) |
EP (1) | EP1292577B1 (hu) |
JP (2) | JP5132861B2 (hu) |
KR (1) | KR100776934B1 (hu) |
CN (1) | CN1321112C (hu) |
AU (2) | AU4589701A (hu) |
BR (1) | BR0108819A (hu) |
CA (1) | CA2400778C (hu) |
CZ (1) | CZ303632B6 (hu) |
ES (1) | ES2398093T3 (hu) |
HK (2) | HK1056164B (hu) |
HU (1) | HU229371B1 (hu) |
IL (2) | IL151418A0 (hu) |
MX (1) | MXPA02009279A (hu) |
NO (1) | NO324054B1 (hu) |
NZ (1) | NZ520875A (hu) |
PL (1) | PL214230B1 (hu) |
RU (1) | RU2276141C9 (hu) |
UA (1) | UA75883C2 (hu) |
WO (1) | WO2001072714A2 (hu) |
ZA (1) | ZA200206534B (hu) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004538285A (ja) * | 2001-07-16 | 2004-12-24 | ユーロ−セルティック エス. ア. | アリール置換チアゾリジノンおよびその使用 |
AR036873A1 (es) * | 2001-09-07 | 2004-10-13 | Euro Celtique Sa | Piridinas aril sustituidas a, composiciones farmaceuticas y el uso de las mismas para la preparacion de un medicamento |
AR037233A1 (es) * | 2001-09-07 | 2004-11-03 | Euro Celtique Sa | Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento |
ATE541847T1 (de) * | 2001-11-01 | 2012-02-15 | Icagen Inc | Pyrazolopyrimidine als natriumkanalblocker |
JP4473583B2 (ja) * | 2002-03-13 | 2010-06-02 | ユーロ−セルティーク エス.エイ. | アリール置換ピリミジン及びその使用 |
EP1532119A2 (en) * | 2002-07-31 | 2005-05-25 | Euro-Celtique S.A. | Aryl substituted benzimidazoles and their use as sodium channel blockers |
US20050227974A9 (en) * | 2002-08-01 | 2005-10-13 | Euro-Celtique S.A. | Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
US20040152696A1 (en) * | 2002-08-01 | 2004-08-05 | Euro-Celtique S.A. | 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers |
JP2007510741A (ja) * | 2003-11-10 | 2007-04-26 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネル遮断薬としての置換トリアゾール類 |
US7531560B2 (en) | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
GB0428012D0 (en) * | 2004-12-22 | 2005-01-26 | Hammersmith Imanet Ltd | Radiolabelling methods |
EP2257536A4 (en) | 2008-02-14 | 2011-03-23 | Amira Pharmaceuticals Inc | CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS |
JP2011518130A (ja) | 2008-04-02 | 2011-06-23 | アミラ ファーマシューティカルズ,インク. | プロスタグランジンd2受容体のアミノアルキルフェニルアンタゴニスト |
US8383654B2 (en) | 2008-11-17 | 2013-02-26 | Panmira Pharmaceuticals, Llc | Heterocyclic antagonists of prostaglandin D2 receptors |
ES2640257T3 (es) * | 2009-05-07 | 2017-11-02 | Medifron Dbt Inc. | Fenilureas y fenilamidas sustituidas como ligandos del receptor vanilloide |
US9212139B2 (en) * | 2010-06-16 | 2015-12-15 | Purdue Pharma, L.P. | Aryl substituted indoles and their use as blockers of sodium channels |
EP2593434A1 (en) | 2010-07-16 | 2013-05-22 | Purdue Pharma LP | Pyridine compounds as sodium channel blockers |
CN103153955A (zh) | 2010-09-17 | 2013-06-12 | 普渡制药公司 | 吡啶化合物及其用途 |
US9045435B2 (en) | 2010-10-05 | 2015-06-02 | Purdue Pharma, L.P. | Quinazoline compounds as sodium channel blockers |
KR20130119964A (ko) | 2010-12-22 | 2013-11-01 | 퍼듀 퍼머 엘피 | 나트륨 채널 차단제로서의 치환된 피리딘 |
AU2012300567B2 (en) | 2011-09-02 | 2016-03-10 | Purdue Pharma L.P. | Pyrimidines as sodium channel blockers |
US9181185B2 (en) | 2011-10-31 | 2015-11-10 | Purdue Pharma L.P. | Heteroaryl compounds as sodium channel blockers |
AU2012321111A1 (en) | 2011-10-31 | 2013-05-16 | Purdue Pharma L.P. | Quaternized amines as sodium channel blockers |
WO2013072758A1 (en) | 2011-11-15 | 2013-05-23 | Purdue Pharma L.P. | Pyrimidine diol amides as sodium channel blockers |
US9206127B2 (en) | 2012-03-16 | 2015-12-08 | Purdue Pharm, L.P. | Substituted pyridines as sodium channel blockers |
US9714252B2 (en) | 2012-12-20 | 2017-07-25 | Purdue Pharma L.P. | Cyclic sulfonamides as sodium channel blockers |
EP3293184B1 (en) | 2013-03-04 | 2020-12-16 | Purdue Pharma L.P. | Pyrimidine carboxamides as sodium channel blockers |
US9120786B2 (en) | 2013-03-04 | 2015-09-01 | Purdue Pharma, L.P. | Triazine carboxamides as sodium channel blockers |
CA2939549C (en) | 2013-03-15 | 2020-08-18 | Purdue Pharma L.P. | Carboxamide derivatives and use thereof |
EP3039019B1 (en) | 2013-08-26 | 2020-04-22 | Purdue Pharma L.P. | Azaspiro[4.5]decane derivatives and use thereof |
US9359330B2 (en) | 2013-08-26 | 2016-06-07 | Purdue Pharma L.P. | Substituted piperidines as sodium channel blockers |
US9828348B2 (en) | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
US9340504B2 (en) | 2013-11-21 | 2016-05-17 | Purdue Pharma L.P. | Pyridine and piperidine derivatives as novel sodium channel blockers |
WO2015094443A1 (en) | 2013-12-20 | 2015-06-25 | Purdue Pharma L.P. | Pyrimidines and use thereof |
CN106103415B (zh) | 2013-12-23 | 2023-02-24 | 普渡制药公司 | 吲唑和其用途 |
US9695144B2 (en) | 2013-12-23 | 2017-07-04 | Purdue Pharma L.P. | Dibenzazepine derivatives and use thereof |
EP3089978B1 (en) | 2013-12-30 | 2018-08-29 | Purdue Pharma L.P. | Pyridone-sulfone morphinan analogs as opioid receptor ligands |
CN106061944A (zh) | 2014-01-24 | 2016-10-26 | 普渡制药公司 | 吡啶类和嘧啶类物质及其用途 |
CA2939501C (en) | 2014-02-12 | 2020-07-07 | Purdue Pharma L.P. | Isoquinoline derivatives and use thereof |
US10730866B2 (en) | 2014-04-07 | 2020-08-04 | Purdue Pharma L.P. | Indole derivatives and use thereof |
WO2015161014A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
MA39956A (fr) | 2014-05-06 | 2015-11-12 | Purdue Pharma Lp | Analogues du benzomorphane et leur utilisation |
WO2015192053A1 (en) | 2014-06-13 | 2015-12-17 | Purdue Pharma L.P. | Azamophinan derivatives and use thereof |
MA40170A (fr) | 2014-06-13 | 2017-04-19 | Purdue Pharma Lp | Dérivés hétérocycliques de morphinan et leur utilisation |
BR112017017619A2 (pt) | 2015-02-19 | 2018-05-08 | Purdue Pharma Lp | métodos e composições para diminuir esvaziamento gástrico |
WO2019195777A1 (en) | 2018-04-06 | 2019-10-10 | Aquinox Pharmaceuticals (Canada) Inc. | Indene derivatives useful in treating pain and inflammation |
CN109369617B (zh) * | 2018-12-13 | 2020-07-31 | 中国科学院福建物质结构研究所 | 一种1-(2-吡啶基)-吡唑-3-甲酸及其衍生物的合成方法 |
EP4003009A4 (en) * | 2019-07-24 | 2023-07-26 | Oregon Health & Science University | SECOND-GENERATION MITOCHONDRIAL PERMEABILITY TRANSITION PORE INHIBITORS WITH ENHANCED PLASMA STABILITY |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3058989A (en) | 1957-11-26 | 1962-10-16 | American Cyanamid Co | Pyridotriazole brighteners |
US3049438A (en) | 1957-11-26 | 1962-08-14 | American Cyanamid Co | Pyridotriazole brighteners |
CH498902A (de) | 1968-07-19 | 1970-11-15 | Geigy Ag J R | Verwendung von Triazolylcumarinen als optische Aufheller in nicht textilen Materialien |
NZ178996A (en) | 1974-11-15 | 1978-06-02 | Kornis G | Pyrfazole amides and thioamides;herbicidal compositions |
DE2910330A1 (de) | 1979-03-16 | 1980-10-02 | Hoechst Ag | 1-phenyl-3-amino-5-hydroxy-1,2,4-triazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4394514A (en) | 1981-04-30 | 1983-07-19 | Smithkline Beckman Corporation | Processes for preparing 4-substituted indoles |
US4454337A (en) | 1981-06-29 | 1984-06-12 | Smithkline Beckman Corporation | Semicarbazide intermediates for preparing 4-substituted indoles |
GB2105327A (en) | 1981-08-17 | 1983-03-23 | Ciba Geigy Ag | Novel 2-phenyl-2H-1,2,3-triazoles and their use in the preparation of fluorescent whitening agents |
DE3215967A1 (de) * | 1982-04-29 | 1983-11-03 | Basf Ag, 6700 Ludwigshafen | Elektrographische aufzeichnungsmaterialien mit speziellen ladungstraeger transportierenden verbindungen |
US4618681A (en) * | 1983-03-18 | 1986-10-21 | The University Of Kentucky Research Foundation | Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants |
DE3525205A1 (de) | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
DE3643403A1 (de) | 1986-12-19 | 1988-06-30 | Shell Agrar Gmbh & Co Kg | Benzophenone und verfahren zu ihrer herstellung |
DE3717038A1 (de) | 1987-05-21 | 1988-12-08 | Basf Ag | Photopolymerisierbare aufzeichnungsmaterialien sowie photoresistschichten und flachdruckplatten auf basis dieser aufzeichnungsmaterialien |
US5015651A (en) | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
PH27357A (en) | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
EP0488959A3 (en) | 1990-11-28 | 1992-08-05 | Sandoz Ltd. | New uses of competitive nmda receptor antagonists |
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
US5550147A (en) | 1992-02-05 | 1996-08-27 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazole derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
SE9302332D0 (sv) * | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
DE4325822A1 (de) * | 1993-07-31 | 1995-02-02 | Hoechst Ag | Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
US5602156A (en) | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
US5744492A (en) | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
SK281577B6 (sk) | 1994-10-18 | 2001-05-10 | Pfizer Inc. | Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze |
US6057346A (en) | 1994-12-12 | 2000-05-02 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of retroviral LTR promoters by calcium response modifiers |
US5741818A (en) * | 1995-06-07 | 1998-04-21 | University Of Saskatchewan | Semicarbazones having CNS activity and pharmaceutical preparations containing same |
GB9601128D0 (en) | 1995-08-11 | 1996-03-20 | Pfizer Ltd | Parasiticidal compounds |
JPH11199566A (ja) | 1997-04-03 | 1999-07-27 | Mitsubishi Chemical Corp | 1−置換−ピラゾール−3−カルボキサミド誘導体およびこれを有効成分とする殺菌剤 |
JP4385414B2 (ja) * | 1997-10-13 | 2009-12-16 | アステラス製薬株式会社 | アミド若しくはアミン誘導体 |
WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
WO1999062885A1 (en) | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
DE20080291U1 (de) | 1999-03-26 | 2002-06-27 | Euro-Celtique S.A., Luxemburg/Luxembourg | Aryl-substituierte Pyrazole, Imidazole, Oxazola, Thiazole und Pyrrole |
US6344563B1 (en) | 1999-08-31 | 2002-02-05 | Timothy Norris | Process for making 5-lipoxygenase inhibitors having varied heterocyclic ring systems |
-
2001
- 2001-03-22 EP EP01918874A patent/EP1292577B1/en not_active Expired - Lifetime
- 2001-03-22 CZ CZ20023486A patent/CZ303632B6/cs not_active IP Right Cessation
- 2001-03-22 HU HU0300867A patent/HU229371B1/hu not_active IP Right Cessation
- 2001-03-22 CA CA2400778A patent/CA2400778C/en not_active Expired - Fee Related
- 2001-03-22 PL PL360534A patent/PL214230B1/pl unknown
- 2001-03-22 CN CNB018068561A patent/CN1321112C/zh not_active Expired - Fee Related
- 2001-03-22 KR KR1020027012598A patent/KR100776934B1/ko not_active IP Right Cessation
- 2001-03-22 AU AU4589701A patent/AU4589701A/xx active Pending
- 2001-03-22 RU RU2002128916/04A patent/RU2276141C9/ru not_active IP Right Cessation
- 2001-03-22 BR BR0108819-0A patent/BR0108819A/pt not_active IP Right Cessation
- 2001-03-22 NZ NZ520875A patent/NZ520875A/en not_active IP Right Cessation
- 2001-03-22 JP JP2001570627A patent/JP5132861B2/ja not_active Expired - Fee Related
- 2001-03-22 ES ES01918874T patent/ES2398093T3/es not_active Expired - Lifetime
- 2001-03-22 AU AU2001245897A patent/AU2001245897B2/en not_active Ceased
- 2001-03-22 UA UA2002108393A patent/UA75883C2/uk unknown
- 2001-03-22 US US09/814,123 patent/US7078426B2/en not_active Expired - Lifetime
- 2001-03-22 IL IL15141801A patent/IL151418A0/xx unknown
- 2001-03-22 WO PCT/US2001/008972 patent/WO2001072714A2/en active IP Right Grant
- 2001-03-22 MX MXPA02009279A patent/MXPA02009279A/es active IP Right Grant
-
2002
- 2002-08-15 ZA ZA200206534A patent/ZA200206534B/en unknown
- 2002-08-22 IL IL151418A patent/IL151418A/en not_active IP Right Cessation
- 2002-09-16 NO NO20024426A patent/NO324054B1/no not_active IP Right Cessation
-
2003
- 2003-06-09 US US10/456,735 patent/US6919363B2/en not_active Expired - Lifetime
- 2003-09-17 HK HK03106683.6A patent/HK1056164B/zh not_active IP Right Cessation
- 2003-10-27 HK HK03107724A patent/HK1055430A1/xx not_active IP Right Cessation
-
2012
- 2012-07-09 JP JP2012153718A patent/JP2012193194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0300867A2 (hu) | Aril-szubsztituált pirazolok, triazolok és tetrazolok és alkalmazásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
GEP20156282B (en) | Compounds and compositions as protein kinase inhibitors | |
HK1097189A1 (en) | Cannabinoid receptor ligands | |
HK1080470A1 (en) | Heterocyclic compounds | |
TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
HK1070054A1 (en) | Arylsulfonyl derivatives with5-ht6 receptor affinity | |
WO2004112710A3 (en) | COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß | |
DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
ATE360630T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
RS20090249A (en) | Spiroketone acetyl-coa carboxylase inhibotors | |
MXPA02012033A (es) | Derivados de 2-aminocarbonil-9h-purina. | |
MY136800A (en) | Inhibitors of the interaction between mdm2 and p53 | |
ATE360631T1 (de) | Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors | |
DE60206911D1 (de) | Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren | |
NO20052182L (no) | Nye forbindelser | |
MXPA05012247A (es) | Derivados de bencimidazol nuevos. | |
SE0402762D0 (sv) | Indazole sulphonamide derivatives | |
UA86776C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение | |
RS97004A (en) | Benzoxazine derivatives as 5-ht6 modulators and uses thereof | |
BRPI0409959A (pt) | uso de derivados de azetidinacarboxamida em terapia | |
SE0102055D0 (sv) | New Compounds | |
ATE383345T1 (de) | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. | |
GEP20084437B (en) | Novel lincomycin derivatives possessing antimicrobial activity | |
UA83832C2 (ru) | Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение | |
ATE247964T1 (de) | Als inhibitoren der aicarftnützliche verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of definitive patent protection due to non-payment of fees |